Novel Agents in Inflammatory Bowel Disease
Crohn’s disease Mechanism Ulcerative colitis Vedoli zumab (approved) Anti-integrin Vedolizumab (approved) Etrolizumab (phase III) Etrolizumab (phase III) PF-00547659 (phase II) PF-00547659 (phase II) Ozanimod (phase II) Sphingosine-1-phosphate inhibitor Ozanimod (phase…